Mink Therapeutics Inc

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its lead candidate, agenT-797, is an off-the-shelf, allogeneic native iNKT cell therapy in Phase 2 trials for advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma, in Phase 1 trials as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors for refractory solid tumors, and in Phase 1 trials for moderate to severe viral acute respiratory distress syndrome (ARDS). The company is also developing MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program for solid tumors and inflammation, and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including graft-versus-host disease prevention. MiNK Therapeutics has collaborations with Autonomous Therapeutics, ImmunoScape, Inc., and C-Further. Formerly known as AgenTus Therapeutics, Inc., it changed its name to MiNK Therapeutics, Inc. in June 2021, was incorporated in 2017, and is based in New York, New York.

INKT▲2

MiNK Therapeutics Reports Q2 2026 Results and Phase 2 Progress

MiNK Therapeutics reported second quarter 2026 financial results and provided an update on its randomized Phase 2 study of agenT-797 in acute lung injury and ARDS. The company ended the quarter with $8.8 million in cash and cash equivalents, compared with $9.5 million at March 31, 2026, and $3.4 million at year-end 2025. Net loss narrowed to $3.1 million, or $0.62 per share, from $4.2 million, or $1.06 per share, in the prior year period. The company initiated dosing in Ukraine and expects U.S. sites to begin enrollment in September 2026, with additional data expected in early 2027. MiNK also launched a paid named-patient access program in Brazil and is preparing for an FDA meeting to discuss a seamless Phase 3 study.

INKT ▲

The Motley Fool·36dRead more →